Technology

ResMed Stock Outlook: Is Wall Street Bullish or Bearish?

2026-02-18 16:10
562 views
ResMed Stock Outlook: Is Wall Street Bullish or Bearish?

ResMed Stock Outlook: Is Wall Street Bullish or Bearish? Resmed Inc_ logo and chart-by IgorGolovniov via Shutterstock Neharika Jain Thu, February 19, 2026 at 12:10 AM GMT+8 2 min read In this article:...

ResMed Stock Outlook: Is Wall Street Bullish or Bearish? Resmed Inc_ logo and chart-by IgorGolovniov via Shutterstock Resmed Inc_ logo and chart-by IgorGolovniov via Shutterstock Neharika Jain Thu, February 19, 2026 at 12:10 AM GMT+8 2 min read In this article:

Diego, California-based ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders. It is valued at a market cap of $37.3 billion.

This healthcare company has outperformed the broader market over the past 52 weeks. Shares of RMD have rallied 12.8% over this time frame, while the broader S&P 500 Index ($SPX) has gained 11.9%. Moreover, on a YTD basis, the stock is up 8.3%, compared to SPX’s marginal drop.

More News from Barchart

  • Cathie Wood Adds 210K Shares to a Rising AI Bet With Upside of 102%

  • Is GOOG Stock a Buy Amid the Software Selloff?

  • Broadcom Is ‘Sitting on a Sinking Iceberg.’ Why 1 Analyst Is Warning on AVGO Stock Here.

  • Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now!

Zooming in further, RMD has also outpaced the iShares U.S. Medical Devices ETF (IHI), which declined 8% over the past 52 weeks and 5% on a YTD basis.

www.barchart.com www.barchart.com

On Jan. 29, shares of RMD closed down marginally after its Q2 earnings release, despite posting better-than-expected results. The company’s revenue increased 11% year-over-year to $1.4 billion, surpassing consensus estimates by 2.2%. On the earnings front, its adjusted EPS of $2.81 advanced 15.6% from the year-ago quarter, topping analyst expectations of $2.69.

For fiscal 2026, ending in June, analysts expect RMD’s EPS to grow 14.9% year over year to $10.97. The company’s earnings surprise history is promising. It topped the consensus estimates in each of the last four quarters.

Among the 19 analysts covering the stock, the consensus rating is a "Moderate Buy,” which is based on eight “Strong Buy,” two "Moderate Buy,” eight “Hold,” and one “Strong Sell” rating.

www.barchart.com www.barchart.com

The configuration is less bullish than three months ago, with nine analysts suggesting a “Strong Buy” rating.

On Feb. 6, Morgan Stanley (MS) analyst David Bailey maintained a "Buy" rating on RMD and set a price target of $310, indicating a 19.1 potential upside from the current levels.

The mean price target of $295.92 suggests a 13.7% potential upside from the current levels, while its Street-high price target of $345 suggests a 32.5% potential upside from the current levels.

On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

Terms and Privacy Policy Privacy Dashboard More Info